-
公开(公告)号：US20060030529A1
公开(公告)日：2006-02-09
申请号：US11218234
申请日：2005-09-01
IPC分类号： A61K38/17
CPC分类号： C07K14/71 , A61K38/00 , A61K38/179 , C07K14/47 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
-
公开(公告)号：US20050163798A1
公开(公告)日：2005-07-28
申请号：US11016097
申请日：2004-12-17
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
-
公开(公告)号：US07303746B2
公开(公告)日：2007-12-04
申请号：US10988243
申请日：2004-11-12
CPC分类号： C07K14/71 , A61K38/00 , C07K2319/00
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
摘要翻译： 公开了具有改善的药代动力学的修饰的嵌合多肽可用于治疗眼睛疾病，包括年龄相关性黄斑变性和糖尿病性视网膜病变。
-
公开(公告)号：US20060166328A1
公开(公告)日：2006-07-27
申请号：US11327555
申请日：2006-01-06
CPC分类号： C07K14/65 , A61K38/30 , C07K2319/00 , C07K2319/30 , C07K2319/75
摘要： A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.
摘要翻译： 包含至少一种IGF1变体组分和融合组分（F）以及任选的信号序列的融合蛋白，其相对于天然IGF1或IGF2多肽表现出改进的稳定性。 融合组分（F）可以是多聚化组分，靶向配体或另一种活性或治疗化合物。 IGF1变体显示相对于天然IGF1具有改善的诱导骨骼肌肥大的能力。
-
公开(公告)号：US20060148705A1
公开(公告)日：2006-07-06
申请号：US11346008
申请日：2006-02-02
申请人： Thomas Daly , James Fandl , Nicholas Papadopoulos
发明人： Thomas Daly , James Fandl , Nicholas Papadopoulos
摘要： Nucleic acid molecules encoding fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
摘要翻译： 编码结合并抑制血管内皮生长因子（VEGF）的融合蛋白的核酸分子。 VEGF结合融合蛋白在治疗VEGF相关病症和疾病中是治疗上有用的，并且被特别设计用于局部给予特定器官，组织和/或细胞。
-
公开(公告)号：US20060058234A1
公开(公告)日：2006-03-16
申请号：US11204709
申请日：2005-08-16
CPC分类号： C07K14/71 , A61K38/00 , C07K2319/00 , C07K2319/30
摘要： Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF). VEGF traps are disclosed which are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
摘要翻译： 能够结合血管内皮生长因子（VEGF）的核酸分子和多聚体蛋白质。 公开了可用于治疗VEGF相关病症和疾病的VEGF陷阱，其专门用于局部给予特定器官，组织和/或细胞。
-
7.发明申请Modified chimeric polypeptides with improved pharmacokinetic properties and methods of making and using thereof 有权具有改善的药代动力学性质的修饰的嵌合多肽及其制备和使用方法公开(公告)号：US20050245447A1
公开(公告)日：2005-11-03
申请号：US11016503
申请日：2004-12-17
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
摘要翻译： 公开了具有改善的药代动力学的修饰的嵌合多肽。 具体地，公开了已经以改善其药代动力学特征的方式修饰的修饰的嵌合Flt1受体多肽。 还公开了制备和使用修饰的多肽的方法，包括但不限于使用修饰的多肽来降低或抑制哺乳动物的血浆渗透和/或血管通透性。
-
公开(公告)号：US20050158829A1
公开(公告)日：2005-07-21
申请号：US11035599
申请日：2005-01-14
申请人： James Fandl , Gang Chen , Nicholas Papadopoulos , Thomas Aldrich
发明人： James Fandl , Gang Chen , Nicholas Papadopoulos , Thomas Aldrich
IPC分类号： C07H21/04 , C07K14/515 , C07K16/28 , C12N5/06
CPC分类号： C07K16/2863 , C07H21/04 , C07K2317/31 , C07K2317/52 , C07K2317/622 , C07K2317/75 , C07K2319/30
摘要： A fusion polypeptide comprising (A)x—M—(A′)y, wherein A and A′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A′ may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different ScFv fragmetns, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
摘要翻译： 一种融合多肽，其包含（A）M-M（A'）y Y，其中A和A'是能够结合靶受体的多肽。 本发明的融合多肽形成激活靶受体的多聚体蛋白。 A和A'可以各自为来自对靶受体特异的抗体的抗体或片段，例如相同或不同的ScFv片段，和/或能够结合靶蛋白的配体或配体片段或衍生物，M是 多聚化组分，X和Y独立地为1-10之间的数。
-
公开(公告)号：US07534604B2
公开(公告)日：2009-05-19
申请号：US11035599
申请日：2005-01-14
CPC分类号： C07K16/2863 , C07H21/04 , C07K2317/31 , C07K2317/52 , C07K2317/622 , C07K2317/75 , C07K2319/30
摘要： A fusion polypeptide comprising (A)x-M-(A′)y, wherein A and A′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A′ may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different ScFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
摘要翻译： 包含（A）x-M-（A'）y的融合多肽，其中A和A'是能够结合靶受体的多肽。 本发明的融合多肽形成激活靶受体的多聚体蛋白。 A和A'可以各自为衍生自靶受体（例如相同或不同ScFv片段）的特异性抗体的抗体或片段，和/或能够结合靶蛋白质的配体或配体片段或衍生物，M为 多聚化组分，X和Y独立地为1-10之间的数。
-
10.发明申请Therapeutic methods for treating vascular eye disorders with DII4 antagonists 审中-公开用DII4拮抗剂治疗血管性眼病的治疗方法公开(公告)号：US20080181893A1
公开(公告)日：2008-07-31
申请号：US11890741
申请日：2007-08-07
IPC分类号： A61K39/395 , A61P27/02
CPC分类号： C07K16/2863 , A61K38/1709 , A61K2039/505 , C07K2317/76 , C07K2319/30
摘要： A therapeutic method for treating ischemic or vascular disorders by administering an agent capable of inhibiting human delta-like ligand 4 (Dll4) activity to a subject in need thereof. In one embodiment, the agent is an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor. The method of the invention is useful for treating eye disorders such as ischemic retinopathy, diabetic retinopathy, age related macular degeneration, corneal neovascularization, neovascular glaucoma, or retinopathy of prematurity. The method is also useful or treating ischemic or vascular disorders such as ischemic injury, cerebral ischemia, cardiac ischemia, ischemic conditions affecting the limbs and other organs or tissues, arteriovenous malformations, wound healing, organ or tissue transplantation, placental insufficiency, arterial narrowing and occlusion, atherosclerosis, and systemic or pulmonary hypertension.
摘要翻译： 一种通过向有需要的受试者施用能够抑制人类δ样配体4（Dll4）活性的试剂来治疗缺血性或血管性疾病的治疗方法。 在一个实施方案中，该试剂是能够抑制Dll4与Notch受体结合的抗Dll4抗体或抗体片段。 本发明的方法可用于治疗眼部疾病如缺血性视网膜病变，糖尿病性视网膜病变，年龄相关性黄斑变性，角膜新生血管形成，新生血管性青光眼或早产儿视网膜病变。 该方法还可用于治疗缺血性或血管性疾病，例如缺血性损伤，脑缺血，心脏缺血，影响肢体和其他器官或组织的缺血状况，动静脉畸形，伤口愈合，器官或组织移植，胎盘功能不全，动脉狭窄和 闭塞，动脉粥样硬化和全身或肺动脉高压。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.017 秒)